Literature DB >> 36016846

Watch and Wait Strategies in NET Patients: More than Expected.

Sebastian Krug1, Anja Rinke2, Marianne Pavel3.   

Abstract

Entities:  

Keywords:  Germany; NET; Survey; Watch-and-wait

Year:  2022        PMID： 36016846      PMCID： PMC9401089          DOI： 10.26502/acmcr.96550511

Source DB:  PubMed          Journal:  Arch Clin Med Case Rep        ISSN： 2575-9655


× No keyword cloud information.
  10 in total

1.  Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  M Pavel; K Öberg; M Falconi; E P Krenning; A Sundin; A Perren; A Berruti
Journal:  Ann Oncol       Date:  2020-04-06       Impact factor: 32.976

2.  Everolimus for advanced pancreatic neuroendocrine tumors.

Authors:  James C Yao; Manisha H Shah; Tetsuhide Ito; Catherine Lombard Bohas; Edward M Wolin; Eric Van Cutsem; Timothy J Hobday; Takuji Okusaka; Jaume Capdevila; Elisabeth G E de Vries; Paola Tomassetti; Marianne E Pavel; Sakina Hoosen; Tomas Haas; Jeremie Lincy; David Lebwohl; Kjell Öberg
Journal:  N Engl J Med       Date:  2011-02-10       Impact factor: 91.245

3.  The European Neuroendocrine Tumour Society registry, a tool to assess the prognosis of neuroendocrine neoplasms.

Authors:  Ivan Borbath; Rocio Garcia-Carbonero; Damir Bikmukhametov; Paula Jimenez-Fonseca; Angel Castaño; Jaroslava Barkmanova; Eva Sedlackova; Attila Kollár; Emanuel Christ; Gregory Kaltsas; Beata Kos-Kudla; Sebastian Maasberg; Chris Verslype; Ulrich-Frank Pape
Journal:  Eur J Cancer       Date:  2022-04-23       Impact factor: 9.162

4.  Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.

Authors:  Anja Rinke; Hans-Helge Müller; Carmen Schade-Brittinger; Klaus-Jochen Klose; Peter Barth; Matthias Wied; Christina Mayer; Behnaz Aminossadati; Ulrich-Frank Pape; Michael Bläker; Jan Harder; Christian Arnold; Thomas Gress; Rudolf Arnold
Journal:  J Clin Oncol       Date:  2009-08-24       Impact factor: 44.544

5.  Lanreotide in metastatic enteropancreatic neuroendocrine tumors.

Authors:  Martyn E Caplin; Marianne Pavel; Jarosław B Ćwikła; Alexandria T Phan; Markus Raderer; Eva Sedláčková; Guillaume Cadiot; Edward M Wolin; Jaume Capdevila; Lucy Wall; Guido Rindi; Alison Langley; Séverine Martinez; Joëlle Blumberg; Philippe Ruszniewski
Journal:  N Engl J Med       Date:  2014-07-17       Impact factor: 91.245

6.  Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study.

Authors:  James C Yao; Nicola Fazio; Simron Singh; Roberto Buzzoni; Carlo Carnaghi; Edward Wolin; Jiri Tomasek; Markus Raderer; Harald Lahner; Maurizio Voi; Lida Bubuteishvili Pacaud; Nicolas Rouyrre; Carolin Sachs; Juan W Valle; Gianfranco Delle Fave; Eric Van Cutsem; Margot Tesselaar; Yasuhiro Shimada; Do-Youn Oh; Jonathan Strosberg; Matthew H Kulke; Marianne E Pavel
Journal:  Lancet       Date:  2015-12-17       Impact factor: 79.321

7.  [Neuroendocrine Neoplasia within the German NET Registry].

Authors: 
Journal:  Z Gastroenterol       Date:  2018-10-10       Impact factor: 2.000

8.  Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States.

Authors:  Arvind Dasari; Chan Shen; Daniel Halperin; Bo Zhao; Shouhao Zhou; Ying Xu; Tina Shih; James C Yao
Journal:  JAMA Oncol       Date:  2017-10-01       Impact factor: 31.777

9.  The Patient's Point of View: COVID-19 and Neuroendocrine Tumor Disease.

Authors:  Sebastian Krug; Maryam Khosravian; Julia Weissbach; Katharina George; Marko Damm; Jakob Garbe; Jens Walldorf; Philipp A Reuken; Tania Amin; Alexander Siebenhüner; Jonas Rosendahl; Thomas M Gress; Patrick Michl; Jörg Schrader; Anja Rinke
Journal:  Cancers (Basel)       Date:  2022-01-26       Impact factor: 6.639

10.  Tumor growth rate as a metric of progression, response, and prognosis in pancreatic and intestinal neuroendocrine tumors.

Authors:  Clarisse Dromain; Marianne E Pavel; Philippe Ruszniewski; Alison Langley; Christine Massien; Eric Baudin; Martyn E Caplin
Journal:  BMC Cancer       Date:  2019-01-14       Impact factor: 4.430
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.